Sequential blockade of the mycobacterial de novo folate pathway. A review.
D000630:Aminopterin / Q000627:therapeutic use; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003622:Dapsone / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D004357:Drug Synergism; D005493:Folic Acid Antagonists / Q000627:therapeutic use*; D006801:Humans; D007918:Leprosy / Q000188:drug therapy*; D009166:Mycobacterium leprae / Q000187:drug effects* / Q000201:enzymology; D009249:NADP; D011739:Pyrimethamine / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D013412:Sulfadimethoxine / Q000627:therapeutic use; D013421:Sulfamethoxypyridazine / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D013762:Tetrahydrofolate Dehydrogenase / Q000378:metabolism
D000900:Anti-Bacterial Agents; D005493:Folic Acid Antagonists; D011743:Pyrimidines; D013449:Sulfonamides; D013412:Sulfadimethoxine; D009249:NADP; D003622:Dapsone; D013762:Tetrahydrofolate Dehydrogenase; D000630:Aminopterin; D013421:Sulfamethoxypyridazine; D012293:Rifampin; D011739:Pyrimethamine